10th Feb 2014 16:47
LONDON (Alliance News) - LONDON (Alliance News) - Vectura Group PLC Monday said partner Sandoz has received marketing authorisation from Norwegian authorities for its asthma inhaler AirFluSal Forspiro.
It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary, Romania, and Bulgaria.
Vectura initially developed the product and created the design of the inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura.
Vectura shares closed up 0.2% at 154.00 pence Monday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L